Literature DB >> 17932975

Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes.

Brenda Banwell1, Amit Bar-Or, Roy Cheung, Julia Kennedy, Lauren B Krupp, Dorothy J Becker, Hans-Michael Dosch.   

Abstract

OBJECTIVES: Pediatric-onset multiple sclerosis offers a unique window into early targets and mechanisms of immune dysregulation. It is unknown whether heightened T-cell reactivities documented in adult patients, to both target-organ and environmental antigens, emerge in parallel or develop as early or late events. Our objectives were to determine the presence, pattern, and specificity of abnormal T-cell reactivities to such antigens in the earliest stages of the multiple sclerosis process.
METHODS: Peripheral T-cell proliferative responses to self-, dietary, and control antigens were blindly evaluated in a large cohort of well-characterized children (n = 172) with central nervous system (CNS) inflammatory demyelination (n = 63), recent-onset type 1 (insulin-dependent) diabetes mellitus (T1D; n = 41), nonautoimmune neurological conditions (n = 39), and healthy children (n = 29).
RESULTS: Children with inflammatory demyelination, CNS injury, and T1D exhibited heightened T-cell reactivities to self-antigens, and these responses were not strictly limited to the disease target organs. Children with autoimmune disease and CNS injury also exhibited abnormal T-cell responses against multiple cow-milk proteins. Responses to specific milk epitopes distinguished T1D from inflammatory demyelination and other neurological diseases.
INTERPRETATION: Abnormal T-cell reactivities to self- and environmental antigens manifest in the earliest clinical stages of inflammatory demyelination and T1D. The pattern of heightened T-cell reactivities implicates both shared and distinct mechanisms of immune dysregulation in the different autoimmune diseases. Abnormal T-cell responses in children with tissue injury challenge the prevailing view that CNS autoreactive cells inherently mediate the disease in early multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17932975     DOI: 10.1002/ana.21244

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  22 in total

Review 1.  Pediatric multiple sclerosis.

Authors:  E Ann Yeh; Tanuja Chitnis; Lauren Krupp; Jayne Ness; Dorothée Chabas; Nancy Kuntz; Emmanuelle Waubant
Journal:  Nat Rev Neurol       Date:  2009-10-13       Impact factor: 42.937

Review 2.  Therapies for multiple sclerosis: considerations in the pediatric patient.

Authors:  Brenda Banwell; Amit Bar-Or; Gavin Giovannoni; Russell C Dale; Marc Tardieu
Journal:  Nat Rev Neurol       Date:  2011-01-11       Impact factor: 42.937

Review 3.  Type 1 diabetes mellitus and multiple sclerosis: common etiological features.

Authors:  Adam E Handel; Lahiru Handunnetthi; George C Ebers; Sreeram V Ramagopalan
Journal:  Nat Rev Endocrinol       Date:  2009-11-03       Impact factor: 43.330

4.  A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis.

Authors:  J M Burton; S Kimball; R Vieth; A Bar-Or; H-M Dosch; R Cheung; D Gagne; C D'Souza; M Ursell; P O'Connor
Journal:  Neurology       Date:  2010-04-28       Impact factor: 9.910

5.  Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis.

Authors:  Samantha Kimball; Reinhold Vieth; Hans-Michael Dosch; Amit Bar-Or; Roy Cheung; Donald Gagne; Paul O'Connor; Cheryl D'Souza; Melanie Ursell; Jodie M Burton
Journal:  J Clin Endocrinol Metab       Date:  2011-06-22       Impact factor: 5.958

6.  Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes.

Authors:  Kevan C Herold; Mark D Pescovitz; Paula McGee; Heidi Krause-Steinrauf; Lisa M Spain; Kasia Bourcier; Adam Asare; Zhugong Liu; John M Lachin; H Michael Dosch
Journal:  J Immunol       Date:  2011-07-20       Impact factor: 5.422

7.  Dietary intake of vitamin D during adolescence and risk of multiple sclerosis.

Authors:  Kassandra L Munger; Tanuja Chitnis; A Lindsay Frazier; Edward Giovannucci; Donna Spiegelman; Alberto Ascherio
Journal:  J Neurol       Date:  2010-10-14       Impact factor: 4.849

8.  Pediatric multiple sclerosis.

Authors:  Emmanuelle Waubant; Dorothee Chabas
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.598

Review 9.  Pediatric multiple sclerosis.

Authors:  Dorothee Chabas; Jonathan Strober; Emmanuelle Waubant
Journal:  Curr Neurol Neurosci Rep       Date:  2008-09       Impact factor: 5.081

Review 10.  Pediatric Multiple Sclerosis: an Update.

Authors:  Scott Otallah; Brenda Banwell
Journal:  Curr Neurol Neurosci Rep       Date:  2018-09-18       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.